Practice Guideline
doi: 10.6004/jnccn.2016.0122.
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
- PMID: 27587625
- DOI: 10.6004/jnccn.2016.0122
Item in Clipboard
Practice Guideline
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw.
2016 Sep.
Abstract
This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and current algorithms were revised for the 2016 update. The new LCOHs algorithms include clear cell carcinomas, mucinous carcinomas, and grade 1 (low-grade) serous carcinomas/endometrioid epithelial carcinomas. The LCOHs also include carcinosarcomas (malignant mixed Müllerian tumors of the ovary), borderline epithelial tumors (also known as low malignant potential tumors), malignant sex cord-stromal tumors, and malignant germ cell tumors.
Copyright © 2016 by the National Comprehensive Cancer Network.
Similar articles
-
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. J Natl Compr Canc Netw. 2021. PMID: 33545690
-
Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.Semin Diagn Pathol. 2005 Feb;22(1):3-32. doi: 10.1053/j.semdp.2005.11.002. Semin Diagn Pathol. 2005. PMID: 16512597 Review.
-
Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.Oncology (Williston Park). 2016 Feb;30(2):166-76. Oncology (Williston Park). 2016. PMID: 26892153 Review.
-
Rare ovarian tumors: an update on diagnosis and treatment.Int J Gynecol Cancer. 2020 Jun;30(6):879-887. doi: 10.1136/ijgc-2020-001235. Epub 2020 May 26. Int J Gynecol Cancer. 2020. PMID: 32461259 Review.
-
Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.Arch Gynecol Obstet. 2019 Feb;299(2):515-523. doi: 10.1007/s00404-018-4952-9. Epub 2018 Nov 10. Arch Gynecol Obstet. 2019. PMID: 30415435
Cited by
-
A risk prediction model of gene signatures in ovarian cancer through bagging of GA-XGBoost models.J Adv Res. 2020 Nov 11;30:113-122. doi: 10.1016/j.jare.2020.11.006. eCollection 2021 May. J Adv Res. 2020. PMID: 34026291 Free PMC article.
-
Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer.Curr Oncol. 2023 Dec 1;30(12):10272-10282. doi: 10.3390/curroncol30120748. Curr Oncol. 2023. PMID: 38132382 Free PMC article.
-
Salient magnetic resonance imaging findings in the differential diagnosis of benign, borderline and malignant ovarian mucinous tumors.Abdom Radiol (NY). 2024 Aug 27. doi: 10.1007/s00261-024-04545-9. Online ahead of print. Abdom Radiol (NY). 2024. PMID: 39187694
-
Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity.Ann Transl Med. 2020 Jul;8(14):905. doi: 10.21037/atm-2019-cm-08. Ann Transl Med. 2020. PMID: 32793749 Free PMC article. Review.
-
Targeting z-Crystallin by aspirin restores the sensitivity to cisplatin in resistant A2780 ovarian cancer cells.Front Pharmacol. 2024 Jul 3;15:1377028. doi: 10.3389/fphar.2024.1377028. eCollection 2024. Front Pharmacol. 2024. PMID: 39021835 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
